Corcept Therapeutics Inc
For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym ®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California.
Generated $672.0 in free cash flow for every $1 of capital expenditure in FY25.
Current Price
$51.42
+10.53%GoodMoat Value
$16.61
67.7% overvaluedCorcept Therapeutics Inc (CORT) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Corcept Therapeutics Inc's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $769.10M. Gross profit (TTM) is $755.64M. EBITDA is $-6.87M. Earnings per share (EPS) is $0.82. The P/E ratio is 117.20. Market capitalization is $5.47B.
Free cash flow (FCF) is $141.78M. FCF growth rate is 0.82%. EPS growth CAGR is 0.69%. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Corcept Therapeutics Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.
